Australia's largest stock trading and investment forum Australia's #1 stock forum

RAP

0.00%

20.5¢ raptor resources limited

Dr Keating Email Interview, page-105

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 105 Last

Share
Profile

Follow
LeeKing

5,887 Posts.

226

17/05/16

08:57

Post #: 17785071
Share

Originally posted by gsad1000 ↑

You are 100% correct, doctors may or may not use the ResApp and many initially won't due to the health administration industry being so backward.

But the factor you must consider is the health consumer and doctor google. The power in the doctor-patient relationship is moving toward the patient and has been for a while. Doctor won't use the app but the patient will before seeing the doctor.

Expand

IIRC, the initial customer for RAP will be telehealth companies. But if you mean that consumers will pressure the telehealth companies to adopt it, then I agree.

Originally posted by gedck ↑

And perhaps also another "potential" perspective to consider:
(i) Patient is presumed clear of infection from initial consultation (tele-health or in person) based on other products / existing approaches.
(ii) Condition of the patient deteriorates and they end up in an ER.
(ii) Doctor in the ER then rapidly diagnoses respiratory infection using ResApp and proper and prompt treatment is given (as expanding and implementing ResApp in emergency room settings was one of the many reasons for the recent CR...).
(iv) Medical industry (and consumers) realise (hopefully) the easiness and effectiveness of ResApp as a frontline diagnostic tool, thus avoiding timely, dangerous and avoidable misdiagnosis.
Just another perspective/scenario to consider....

Expand

Yes, if Resapp consistently outperforms other methods, then it will come to dominate the market.

I'm still gasping for the adult results.

RAP Price at posting: 25.0¢ Sentiment: Hold Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BUX

Buxton projects new graphite province discovery at WA Narryer play

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

There are more pages in this discussion • 3 more messages in this thread...

First 105 Last

Add RAP (ASX) to my watchlist

Dr Keating Email Interview, page-105

Top Stories

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Buxton projects new graphite province discovery at WA Narryer play

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

BCI reaches close of funding facility for salt-first part of Mardie project

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Featured News